These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 32751805)

  • 1. Concurrent
    Malarikova D; Berkova A; Obr A; Blahovcova P; Svaton M; Forsterova K; Kriegova E; Prihodova E; Pavlistova L; Petrackova A; Zemanova Z; Trneny M; Klener P
    Cancers (Basel); 2020 Jul; 12(8):. PubMed ID: 32751805
    [TBL] [Abstract][Full Text] [Related]  

  • 2. High-dose cytarabine does not overcome the adverse prognostic value of CDKN2A and TP53 deletions in mantle cell lymphoma.
    Delfau-Larue MH; Klapper W; Berger F; Jardin F; Briere J; Salles G; Casasnovas O; Feugier P; Haioun C; Ribrag V; Thieblemont C; Unterhalt M; Dreyling M; Macintyre E; Pott C; Hermine O; Hoster E;
    Blood; 2015 Jul; 126(5):604-11. PubMed ID: 26022239
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Aggressive morphologic variants of mantle cell lymphoma characterized with high genomic instability showing frequent chromothripsis, CDKN2A/B loss, and TP53 mutations: A multi-institutional study.
    Streich L; Sukhanova M; Lu X; Chen YH; Venkataraman G; Mathews S; Zhang S; Kelemen K; Segal J; Gao J; Gordon L; Chen Q; Behdad A
    Genes Chromosomes Cancer; 2020 Aug; 59(8):484-494. PubMed ID: 32277542
    [TBL] [Abstract][Full Text] [Related]  

  • 4.
    Eskelund CW; Dahl C; Hansen JW; Westman M; Kolstad A; Pedersen LB; Montano-Almendras CP; Husby S; Freiburghaus C; Ek S; Pedersen A; Niemann C; Räty R; Brown P; Geisler CH; Andersen MK; Guldberg P; Jerkeman M; Grønbæk K
    Blood; 2017 Oct; 130(17):1903-1910. PubMed ID: 28819011
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Whole genome copy number analysis in search of new prognostic biomarkers in first line treatment of mantle cell lymphoma. A study by the LYSA group.
    Le Bris Y; Magrangeas F; Moreau A; Chiron D; Guérin-Charbonnel C; Theisen O; Pichon O; Canioni D; Burroni B; Maisonneuve H; Thieblemont C; Oberic L; Gyan E; Pellat-Deceunynck C; Hermine O; Delfau-Larue MH; Tessoulin B; Béné MC; Minvielle S; Le Gouill S
    Hematol Oncol; 2020 Oct; 38(4):446-455. PubMed ID: 32472610
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prognostic Role of CDKN2A Deletion and p53 Expression and Association With MIPIb in Mantle Cell Lymphoma.
    Gaudio F; Dicataldo M; Di Giovanni F; Cazzato G; d'Amati A; Perrone T; Masciopinto P; Laddaga FE; Musto P; Maiorano E; Ingravallo G
    Clin Lymphoma Myeloma Leuk; 2023 Aug; 23(8):599-605. PubMed ID: 37147150
    [TBL] [Abstract][Full Text] [Related]  

  • 7. ATM and TP53 mutations show mutual exclusivity but distinct clinical impact in mantle cell lymphoma patients.
    Mareckova A; Malcikova J; Tom N; Pal K; Radova L; Salek D; Janikova A; Moulis M; Smardova J; Kren L; Mayer J; Trbusek M
    Leuk Lymphoma; 2019 Jun; 60(6):1420-1428. PubMed ID: 30626249
    [TBL] [Abstract][Full Text] [Related]  

  • 8. TP53 and CDKN2A mutations in patients with early-stage lung squamous cell carcinoma: an analysis of the correlations and prognostic outcomes.
    Wang P; Wang F; He H; Chen Y; Lin H; Chen P; Chen X; Liu S
    Ann Transl Med; 2021 Aug; 9(16):1330. PubMed ID: 34532467
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sequencing-based analysis of clonal evolution of 25 mantle cell lymphoma patients at diagnosis and after failure of standard immunochemotherapy.
    Karolová J; Kazantsev D; Svatoň M; Tušková L; Forsterová K; Maláriková D; Benešová K; Heizer T; Dolníková A; Klánová M; Winkovska L; Svobodová K; Hojný J; Krkavcová E; Froňková E; Zemanová Z; Trněný M; Klener P
    Am J Hematol; 2023 Oct; 98(10):1627-1636. PubMed ID: 37605345
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Complex analysis of the TP53 tumor suppressor in mantle cell and diffuse large B-cell lymphomas.
    Zlamalikova L; Moulis M; Ravcukova B; Liskova K; Malcikova J; Salek D; Jarkovsky J; Svitakova M; Hrabalkova R; Smarda J; Smardova J
    Oncol Rep; 2017 Oct; 38(4):2535-2542. PubMed ID: 28791403
    [TBL] [Abstract][Full Text] [Related]  

  • 11. TP53 mutations are common in mantle cell lymphoma, including the indolent leukemic non-nodal variant.
    Sakhdari A; Ok CY; Patel KP; Kanagal-Shamanna R; Yin CC; Zuo Z; Hu S; Routbort MJ; Luthra R; Medeiros LJ; Khoury JD; Loghavi S
    Ann Diagn Pathol; 2019 Aug; 41():38-42. PubMed ID: 31132650
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Toward a Risk-Tailored Therapeutic Policy in Mantle Cell Lymphoma.
    Condoluci A; Rossi D; Zucca E; Cavalli F
    Curr Oncol Rep; 2018 Aug; 20(10):79. PubMed ID: 30132080
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tumoral TP53 and/or CDKN2A alterations are not reliable prognostic biomarkers in patients with localized Ewing sarcoma: a report from the Children's Oncology Group.
    Lerman DM; Monument MJ; McIlvaine E; Liu XQ; Huang D; Monovich L; Beeler N; Gorlick RG; Marina NM; Womer RB; Bridge JA; Krailo MD; Randall RL; Lessnick SL;
    Pediatr Blood Cancer; 2015 May; 62(5):759-65. PubMed ID: 25464386
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mantle cell lymphoma-variant Richter syndrome: Detailed molecular-cytogenetic and backtracking analysis reveals slow evolution of a pre-MCL clone in parallel with CLL over several years.
    Klener P; Fronkova E; Berkova A; Jaksa R; Lhotska H; Forsterova K; Soukup J; Kulvait V; Vargova J; Fiser K; Prukova D; Alam M; Calvin Lenyeletse Maswabi B; Michalova K; Zemanova Z; Jancuskova T; Pekova S; Trneny M
    Int J Cancer; 2016 Nov; 139(10):2252-60. PubMed ID: 27407063
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Genetic mutations and features of mantle cell lymphoma: a systematic review and meta-analysis.
    Hill HA; Qi X; Jain P; Nomie K; Wang Y; Zhou S; Wang ML
    Blood Adv; 2020 Jul; 4(13):2927-2938. PubMed ID: 32598477
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Genomic landscape and prognostic analysis of mantle cell lymphoma.
    Yang P; Zhang W; Wang J; Liu Y; An R; Jing H
    Cancer Gene Ther; 2018 Jun; 25(5-6):129-140. PubMed ID: 29755111
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Detection of gene copy number aberrations in mantle cell lymphoma by a single quantitative multiplex PCR assay: clinicopathological relevance and prognosis value.
    Jardin F; Picquenot JM; Parmentier F; Ruminy P; Cornic M; Penther D; Bertrand P; Lanic H; Cassuto O; Humbrecht C; Lemasle E; Wautier A; Bastard C; Tilly H
    Br J Haematol; 2009 Sep; 146(6):607-18. PubMed ID: 19594747
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mutation and genomic deletion status of ataxia telangiectasia mutated (ATM) and p53 confer specific gene expression profiles in mantle cell lymphoma.
    Greiner TC; Dasgupta C; Ho VV; Weisenburger DD; Smith LM; Lynch JC; Vose JM; Fu K; Armitage JO; Braziel RM; Campo E; Delabie J; Gascoyne RD; Jaffe ES; Muller-Hermelink HK; Ott G; Rosenwald A; Staudt LM; Im MY; Karaman MW; Pike BL; Chan WC; Hacia JG
    Proc Natl Acad Sci U S A; 2006 Feb; 103(7):2352-7. PubMed ID: 16461462
    [TBL] [Abstract][Full Text] [Related]  

  • 19. An Aggressive Presentation of Mantle Cell Lymphoma With Unique Molecular Features.
    Inamdar AA; Loo A; Mikhail N; Lee P
    Cureus; 2021 Aug; 13(8):e17598. PubMed ID: 34646650
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cyclin dependent kinase inhibitor 2A/B gene deletions are markers of poor prognosis in Indian children with acute lymphoblastic leukemia.
    Agarwal M; Bakhshi S; Dwivedi SN; Kabra M; Shukla R; Seth R
    Pediatr Blood Cancer; 2018 Jun; 65(6):e27001. PubMed ID: 29446543
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.